2020
DOI: 10.1136/bmjopen-2020-039067
|View full text |Cite
|
Sign up to set email alerts
|

Randomised, double-blind, multicentre, phase Ⅰ/Ⅱ dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol

Abstract: IntroductionPsoriasis is a life-long, immune-mediated disease that greatly reduces the quality of life of patients. Plaque psoriasis is the most common form of psoriasis. Treatment options for plaque psoriasis with good tolerance and sufficient response remain profoundly limited. Based on mechanistic findings that suggest the key pathogenic role of interleukin (IL)-17 in plaque psoriasis, we hypothesise that GR1501, a new monoclonal antibody (IL-17A targeted), will be an efficacious treatment for plaque psoria… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…The PASI score was used to evaluate the severity of psoriasis-like skin lesion, which was calculated as follows: 24 …”
Section: Methodsmentioning
confidence: 99%
“…The PASI score was used to evaluate the severity of psoriasis-like skin lesion, which was calculated as follows: 24 …”
Section: Methodsmentioning
confidence: 99%